Abstract: In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls having a structure represented by a formula: derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with ?-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Peptides useful as inflammasome inhibitors are disclosed and can comprise an H2 helix of a pyrin domain, wherein at least two non-consecutive amino acids of the H2 helix are covalently linked. Methods of treating a subject with a disease comprising administering to the subject the disclosed peptides are also disclosed. Further, disclosed herein are methods of inhibiting binding between a first polypeptide comprising a pyrin domain and a second polypeptide comprising a pyrin domain, the method comprising contacting either the first polypeptide or the second polypeptide with the disclosed peptides.

Abstract: Disclosed are inhibitors for the ?-catenin/T-cell factor interaction. The inhibitors are selective for ?-catenin/T-cell factor over ?-catenin/phosphocadherin, and ?-catenin/phosphoAPC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed is an underwater robot for a mine flooding rescue, including a starting unit configured to control the implementation of a whole rescue action; a drive unit connected with the starting unit and configured to provide a robot with power to move; and an execution unit connected with the drive unit and configured to salvage underwater life sources.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: The present disclosure provides inhibitors of the beta-catenin/B-cell lymphoma 9 interaction as well as their use in the treatment of oncological disorders. Further provided herein are methods of treating or preventing cancer in a subject, comprising administering to the subject an effective amount of a compound or composition as disclosed herein.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Peptides useful as inflammasome inhibitors are disclosed and can comprise an H2 helix of a pyrin domain, wherein at least two non-consecutive amino acids of the H2 helix are covalently linked. Methods of treating a subject with a disease comprising administering to the subject the disclosed peptides are also disclosed. Further, disclosed herein are methods of inhibiting binding between a first polypeptide comprising a pyrin domain and a second polypeptide comprising a pyrin domain, the method comprising contacting either the first polypeptide or the second polypeptide with the disclosed peptides.

Abstract: Described herein are small molecule inhibitors of the ?-catenin/B-cell lymphoma 9 interaction and pharmaceutical compositions including a therapeutically effective amount of the small molecule inhibitors described herein. Described are also methods of treating oncological disorders, for example cancer by administering the small molecule inhibitors of the ?-catenin/B-cell lymphoma interaction described herein.

Abstract: Disclosed are TATE derivatives having a linker between the TATE moiety and a macrocyclic radionuclide chelating moiety. Methods of synthesis and use are also disclosed. The compounds preferably exhibit a ratio of kidney: liver uptake by a subject within 24 hours of 5 or less, 3 or less, 1 or less, 0.5 or less, preferably from 2:1 to 1:2.

Abstract: Disclosed is an underwater robot for a mine flooding rescue, including a starting unit configured to control the implementation of a whole rescue action; a drive unit connected with the starting unit and configured to provide a robot with power to move; and an execution unit connected with the drive unit and configured to salvage underwater life sources.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadhenin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin in-teractions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: The present disclosure relates to real-time localization error correction of an autonomous vehicle (AV). A processor for real-time localization error correction of the AV is provided. The processor is configured to retrieve a reference landmark around the AV from a map aggregating server (MAS), wherein the AV is configured to interact with the MAS for real-time localization; detect, in real time, a ground truth landmark corresponding to the reference landmark, according to image data captured by one or more image capture devices installed on the AV; and determine a deviation between the ground truth landmark and the reference landmark as a real-time correction value for the real-time localization of the AV.

Abstract: In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls, derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with ?-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over ?-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: In one aspect, the invention relates to 4-substituted benzoylpiperazine-1-substituted carbonyls having a structure represented by a formula: derivatives thereof, and related compounds; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with ?-catenin/BCL9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Disclosed are inhibitors for the ?-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for ?-catenin/B-cell lymphoma 9 over ?-catenin/E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/BCL9 interaction. The inhibitors are selective for ?-catenin/BCL9 over D catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Abstract: Disclosed are inhibitors for the ?-catenin/T-cell factor interaction. The inhibitors are selective for ?-catenin/T-cell factor over ?-catenin/cadherin and ?-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.